#USA #Minneapolis #Medical Devices #VentureMed Group #Bruce Fiedler

VentureMed Group Welcomes Bruce Fiedler as CFO

In a significant announcement made on February 11, 2026, VentureMed Group, Inc., a frontrunner in the medical device sector, confirmed the appointment of Bruce Fiedler as their new Chief Financial Officer (CFO). Fiedler, who has a robust history of financial leadership, is expected to bolster VentureMed's capability to expand its innovative medical technology offerings.

vFiedler brings a wealth of experience, particularly from his previous role at Boston Scientific, where he served as Vice President and Global Controller for the Neuromodulation Division. His contributions there included overseeing critical financial planning and control functions that supported a major global business unit. Fiedler's track record showcases a commitment to operational excellence, financial discipline, and effective cross-functional collaboration, vital for a company like VentureMed that specializes in access management and vessel preparation technologies, particularly for vascular procedures.

In his upcoming role at VentureMed, he will oversee various critical financial activities, including strategic planning, financial reporting, capital allocation, and investor relations. His leadership is anticipated to further the company’s ongoing commitment to developing groundbreaking interventionist vascular solutions for healthcare providers and patients around the globe.

Denis Harrington, President and CEO of VentureMed Group, expressed his enthusiasm about the new addition to the leadership team, stating, "We are pleased to welcome Bruce to our leadership team. His financial expertise and experience in scaling operations within the medical device industry will be invaluable as we enter our next phase of growth. Bruce's strategic leadership will strengthen our financial foundation and position us for long-term value creation."

Fiedler articulated his excitement about joining the venture, stating, “I am thrilled to join the organization at such a pivotal time. I look forward to collaborating with the team to accelerate growth and help patients and physicians.”

VentureMed Group is recognized for its innovative FLEX Vessel Prep™ System, a breakthrough in medical technology designed to optimize vascular preparation through its proprietary Kinetic Endovascular Micro-incision Creation (KEMIC) technique. Unlike traditional balloon-based methodologies that apply static pressure, KEMIC employs controlled movement and dynamic vessel apposition to produce long, precise micro-incisions. This advanced technology represents a significant advancement in the treatment of arteriovenous fistulas, grafts, and peripheral vascular diseases.

With Fiedler's guidance, the company is well-positioned to continue its trajectory in growth while further enhancing its product offerings to improve patient care. The appointment is seen not only as a pivotal strategic move but also as an indication of VentureMed’s priorities in ensuring strong financial management amidst expanding operations.

For those interested in exploring more about VentureMed Group and their innovative portfolio, further information can be accessed at www.VentureMedgroup.com.

About VentureMed Group

VentureMed Group is a pioneering private medical device company based in Minnesota, dedicated to developing endovascular solutions for arteriovenous accesses and interventions for peripheral vascular diseases. Its flagship product, the FLEX Vessel Prep™ System, possesses FDA 510(k) clearance and CE marking, highlighting its compliance with the highest standards in medical device innovation and safety.